openPR Logo
Press release

Immuno-Oncology Market to grow at a CAGR of 21.5% by 2025| Industry Trends, Segment Analysis, Market Share Insights, Competitive Benchmarking, Regional Outlook | Industry participants: Bristol-Myers Squibb, Merck, AstraZeneca, Pfizer Inc. and others.

02-12-2019 12:12 PM CET | Health & Medicine

Press release from: Polaris Market Research & Consulting

immuno oncology IO market

immuno oncology IO market

The Global Immuno-Oncology Market Size was estimated to at USD 8,333.0 billion in 2017. Immuno-oncology, also called as cancer immunotherapy is a biologic treatment, which enhances the body’s natural defenses to stop the growth of cancer. This therapy uses constituents made by the body or in a research laboratory to improve or reestablish the immune system function.

Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Currently, world is at the forefront of this science with several compounds in development that are being investigated for use in a variety of cancers, as well as an approved immuno-oncology medicine that continues to be studied for new uses.

Request for sample pages of Immuno Oncology (I-O) Market Analysis: https://bit.ly/2DuztVt

The more precise targeting of patients for selected therapies is another important area of focus in oncology. Clinical biomarkers and pharmacogenomic studies are increasingly used to identify groups and sub-groups of patients most likely to benefit from an investigational agent in order to maximize its potential benefits.

The global immuno-oncology market is driven by the factors such as rising occurrence of different forms of cancer, technological advancements in the field of immune oncology for cancer treatment, and rising awareness concerning the benefits of ablation procedures over conventional treatment procedures.

Moreover, rising number of ablations centers, surgical centers, and hospitals are driving the growth of tumor ablation market globally. Additionally, the developments in oncology treatments, leading to the increased development of pioneering products are also advancing towards significant growth of the global Immune Oncology market.

The increasing trend was also seen in the research in the novel agents and increase in the number of clinical trials in combinations as well as monotherapy. The most notable new agents in Immuno-Oncology are IDO’s, LAG-3, TIGIT, TIM-3, VISTA, KIR, NKG2A, B7-H3/H4. The Report has also emphasized on the Oncolytic viruses, Neo-Antigen therapies, TCR Therapies and CAR-T therapies.

On the basis of treatment type, the global immuno-oncology market is segmented into Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines. Checkpoint inhibitors were the largest treatment process segment in 2017 that accounted for 54.7% of the overall revenue. On the basis of novel targets, the global market is segmented into IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i. VEGFi was the largest novel target segment that was used for immuno-oncology treatment processes in 2017 with a total market share of 11.2%. on the basis of cancer type, the global immuno-oncology Market is segmented into Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Head, face & Neck Cancer, Bladder Cancer, Classical Hodgkin’s Lymphoma, Merkel Cell, and carcinoma. Revenue share of immuno-oncology treatment for classical hodgkin’s lymphoma was the largest in 2017 i.e. 15.31% among the listed tumor types in the report.

Browse report summary of Immuno Oncology (I-O) Market Analysis: https://bit.ly/2E4YRTc

On the basis of geography, North America was the largest regional market in 2017. High levels of spending on cancer treatments, also U.S. being one of the major country y with a huge population of cancer affected people on a global scale, the country being the host to the development of this technology, higher frequency of innovations of immuno oncology treatments or processes in the region specially in the U.S. etc., all of these factors have driven significant investment and alongside the demand for IO in the region. These factors have driven the North American market since the inception of this technology and over the forecast period it is expected to increase further.

By Segments:

Immuno-Oncology by Treatment Approaches

• Monoclonal Antibodies
• Therapeutic Vaccines
• Checkpoint Inhibitors
• Cytokines

Immuno-Oncology by Novel Targets

• IDO1i
• LAG-3 CPI
• oncolytic virus
• STING agonist
• TLR agonist
• HDACi
• TIL
• VEGFi
• MEKi
• TIGIT
• CPI
• GITR agonist
• TGF-b trap
• A2AR antagonist/CD73i

Immuno-Oncology by Tumor Types

• Melanoma,
• Non-Small Cell Lung Cancer,
• Renal Cell Carcinoma,
• Head & Neck Cancer,
• Bladder Cancer,
• Classical Hodgkin’s Lymphoma
• Merkel Cell Carcinoma

Immuno-Oncology by Regions

• North America [U.S., Canada, Mexico]
• Europe [Germany, UK, France]
• Asia-Pacific [China, India, Japan, Rest of Asia-Pacific]
• Latin America [ Brazil, Mexico]
• Middle East and Africa

Some of the key players operating in global immuno-oncology market:

• Bristol Myers Squibb
• Merck
• AstraZeneca
• Roche Holding AG
• Pfizer Inc.
• Incyte Corporation

Make an inquiry before buying of Immuno Oncology (I-O) Market Analysis: https://bit.ly/2I9po5E

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers.

Contact us

Mr. Rohit
Corporate Sales, USA
Polaris Market Research
Phone: 1-646-568-9980
Email: sales@polarismarketresearch.com
Web: www.polarismarketresearch.com
Blogs- https://healthcare-market-insights.blogspot.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Immuno-Oncology Market to grow at a CAGR of 21.5% by 2025| Industry Trends, Segment Analysis, Market Share Insights, Competitive Benchmarking, Regional Outlook | Industry participants: Bristol-Myers Squibb, Merck, AstraZeneca, Pfizer Inc. and others. here

News-ID: 1580500 • Views: 173

More Releases from Polaris Market Research & Consulting

What's driving the Blockchain Technology Market Trends? Microsoft Corporation, I …
The worldwide market size for blockchain technology is estimated to grow at a CAGR of 41.6% between 2018 and 2026 and is anticipated to reach USD 16.82 billion by 2026. According to a new study published by Polaris Market Research. Also termed as Distributed Ledger Technology (DLT), blockchain enables secure transaction over a distributed network. Since the transactions are taken place usually over the network, it is difficult to reverse
What's driving the Precision Farming Market Trends? Ag Leader Technology, AgJunc …
The global precision farming/agriculture market was valued at 3,833 million in 2017 and is anticipated to reach over USD 13,016 million by 2026 with grow at a CAGR of more than 14.7% during the forecast period According to a new study published by Polaris Market Research. In 2017, the yield monitoring application dominated the global market, in terms of revenue. North America is expected to be the leading contributor to
What are the different trends in Electric Vehicles (EV) Market to boost its grow …
Polaris Market Research has new report published the addition of the “The global Electric Vehicles Market Worth $912 Billion By 2026 | CAGR: 38.4%”, the report classifies the global Electric Vehicles market in a precise manner to offer unearth valuable, accurate and reliable data insights that help organizations to meet their business objectives and enable growth Get PDF Sample of “Electric Vehicles Market”: https://www.polarismarketresearch.com/industry-analysis/electric-vehicles-ev-market/request-for-sample The global electric vehicles market is anticipated to
What are the different trends in Third Party Logistics Market to boost its growt …
Polaris Market Research has new report published the addition of the “The global third-party logistics market is anticipated to reach USD 1,337.91 billion by 2026”, the report classifies the global third-party logistics market in a precise manner to offer unearth valuable, accurate and reliable data insights that help organizations to meet their business objectives and enable growth according to a new report The report “Third Party Logistics (3PL) Market Share, Size,

All 5 Releases


More Releases for Immuno

Cell Therapy to Transform Immuno Oncology Landscape
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
Immuno Oncology Assays Market Expected to Dominate Worldwide by 2026
Global Immuno Oncology Assays Market Analysis According to Verified Market Research, The Global Immuno Oncology Assays Market was valued at USD 2.76 Billion in 2018 and is projected to reach USD 6.96 Billion by 2026, growing at a CAGR of 12.19% from 2019 to 2026. What is Immuno Oncology Assays? Immuno oncology assays is a next-generation sequencing application that provides real-time automated measurements of immune and tumor cells dynamics. With the help of
Immuno-Oncology Conference, London – agenda released
Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies. SMi's Immuno-Oncology Conference (26 – 27 September 2018, London, UK) will focus on a few key areas of the field with representation of the whole industry, under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress. Agenda - Valuable time is spent to
Immuno-Oncology Strategic Insight - Multi-Indication And Market Size Analysis
Latest industry research report on: Immuno-Oncology Strategic Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts GlobalData estimates that the total IO market will be worth approximately $14 billion in 2019, rising to $34 billion by 2024 in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). The main drivers of this growth will come from immune checkpoint inhibitors, which will have sales of approximately
Immuno-Oncology Market Stood at US$ 27,846.3 Mn by 2025
PMR is its report has profiled some of the leading companies operating in the global immuno-oncology market, which includes Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb, Dendreon Corporation, F.Hoffmann-La Roche, Merck & Co., Inc. Novartis AG, Pfizer, Inc., Sanofi. In terms of revenue share, Bristol-Myers Squibb (BMS) was ranked at the top in 2016, thanks to the success of its blockbuster products Opdivo and Yervoy. Owing to higher efficiency as compared to
Global Immuno-Oncology Market will Reach US$ 27,846.3 Mn
Owing to higher efficiency as compared to conventional therapies such as radiation, chemo and surgery, doctors around the globe are increasingly prescribing immunotherapy to cancer patients. Immuno-oncology therapies have low toxicity, making it easier for the patients to undergo such treatment procedures. Increasing clinical approval of immunotherapy drugs continues to support speedy adoption of immuno-oncology treatments while higher investments to further improve immunotherapies is anticipated to create greater market opportunities